Elinzanetant produced a statistically significant reduction in frequency of treatment-related vasomotor symptoms as early as week 1 and in severity at weeks 4 and 12.
Those least likely to schedule further screening mammograms had received a false-positive with recommendation for follow-up after only a short interval.
Regulations have been amended under the Mammography Quality Standards Act of 1992 to ensure women receive quality mammography for early breast cancer detection and prevention.
GLP-1RAs were associated with a significantly reduced risk of obesity-associated cancers including gallbladder cancer, pancreatic cancer, and meningioma.